Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
Go back to Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 64.67 -1.8 (2.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.47 | 52 Week High | $5.17 | |||
| Open | $66.13 | 52 Week Low | $0.94 | |||
| Day High | $66.25 | P/E | N/A | |||
| Day Low | $64.50 | EPS | $0.00 | |||
| Volume | 2,381,092 | |||||
